Science

Apabetalone (RVX-208) is a first-in-class small molecule that inhibits BET bromodomain proteins. The Phase 3 clinical trial BETonMACE is advancing with a primary endpoint of time to first occurrence of Major Adverse Cardiac Events (MACE) in high-risk cardiovascular disease (CVD) patients with type 2 diabetes mellitus and low high-density lipoprotein (HDL).

SCIENCE BEHIND APABETALONE

Apabetalone provides a novel approach to reduce Major Adverse Cardiac Events (MACE) in cardiovascular disease (CVD) patients with type 2 diabetes mellitus and low high-density liprprotein (HDL). CVD is a multifactoral disease with a variety of contributors, many of which are modulated by epigenetic gene regulation governed by BET proteins.

Discover

THE BET
PLATFORM

Our drug development platform targets the Bromodomain and ExtraTerminal Domain (BET) family of proteins. Each of these proteins contain two small regions called 'bromodomains,' which play a role in regulating disease causing genes. Compounds that disrupt the interaction of these domains may have favorable effects on reducing the level of proteins that play a role in disease.

Explore